5-1 g/m2 (body surface area) as fine granule] of flecainide acetate
daily in two to three divided doses.
tablets USP are also indicated for the prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.
a Mylan subsidiary, will be shipping Flecainide Acetate
to the institutional marketplace in unit dose strips (10 X 10's) for the 50 mg and 100 mg strengths.
5-1 g/m2 (body surface area) of fine granules] of flecainide acetate
per day, taken orally and divided into two or three equally spaced doses.
In 2002, the total sales of Flecainide Acetate
Tablets totaled $105.
is available in 50mg, 100mg and 150mg tablet dosage strengths, and has current annual brand sales of approximately $110 million.
is the generic form of Tambocor(R) and omeprazole is the generic form of Prilosec(R).
The filings include ANDAs for megestrol acetate oral suspension (Megace Oral Suspension(R)) (tentatively approved), flecainide acetate
tablets (Tambocor(R)) and fluoxetine 10 mg and 20 mg tablets and 40 mg capsules (Prozac(R)) (tentatively approved) which we believe are first-to-file opportunities and may entitle the Company to up to 180 days of marketing exclusivity after FDA approval.
As previously announced, these filings include ANDAs for megestrol acetate oral suspension (Megace Oral Suspension(R)), flecainide acetate
tablets (Tambocor(R)), fluoxetine tablets (Prozac(R)) and buspirone 7.